RU2145235C1 - Терапевтическая комбинация, содержащая человеческий интерферон, фармацевтический препарат на основе интерферона (варианты) - Google Patents

Терапевтическая комбинация, содержащая человеческий интерферон, фармацевтический препарат на основе интерферона (варианты) Download PDF

Info

Publication number
RU2145235C1
RU2145235C1 RU95113492A RU95113492A RU2145235C1 RU 2145235 C1 RU2145235 C1 RU 2145235C1 RU 95113492 A RU95113492 A RU 95113492A RU 95113492 A RU95113492 A RU 95113492A RU 2145235 C1 RU2145235 C1 RU 2145235C1
Authority
RU
Russia
Prior art keywords
interferon
hepatitis
human
treatment
precursor
Prior art date
Application number
RU95113492A
Other languages
English (en)
Russian (ru)
Other versions
RU95113492A (ru
Inventor
Прьето Валтуена Хесус
Белоки Руис Оскар
Original Assignee
Дзе Веллкам Фаундейшн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Веллкам Фаундейшн Лимитед filed Critical Дзе Веллкам Фаундейшн Лимитед
Publication of RU95113492A publication Critical patent/RU95113492A/ru
Application granted granted Critical
Publication of RU2145235C1 publication Critical patent/RU2145235C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3476—Powered trocars, e.g. electrosurgical cutting, lasers, powered knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3494—Trocars; Puncturing needles with safety means for protection against accidental cutting or pricking, e.g. limiting insertion depth, pressure sensors
    • A61B17/3496—Protecting sleeves or inner probes; Retractable tips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1487—Trocar-like, i.e. devices producing an enlarged transcutaneous opening
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • A61B17/32075—Pullback cutting; combined forward and pullback cutting, e.g. with cutters at both sides of the plaque
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3209—Incision instruments
    • A61B17/3211—Surgical scalpels, knives; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3474—Insufflating needles, e.g. Veress needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053—Mechanical features of the instrument of device
    • A61B2018/00184—Moving parts
    • A61B2018/0019—Moving parts vibrating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • A61M13/003—Blowing gases other than for carrying powders, e.g. for inflating, dilating or rinsing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Plasma & Fusion (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU95113492A 1992-12-22 1993-12-20 Терапевтическая комбинация, содержащая человеческий интерферон, фармацевтический препарат на основе интерферона (варианты) RU2145235C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9226729.3 1992-12-22
GB929226729A GB9226729D0 (en) 1992-12-22 1992-12-22 Therapeutic combination
PCT/GB1993/002600 WO1994014473A1 (en) 1992-12-22 1993-12-20 Therapeutic combination containing interferon

Publications (2)

Publication Number Publication Date
RU95113492A RU95113492A (ru) 1997-08-27
RU2145235C1 true RU2145235C1 (ru) 2000-02-10

Family

ID=10727038

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95113492A RU2145235C1 (ru) 1992-12-22 1993-12-20 Терапевтическая комбинация, содержащая человеческий интерферон, фармацевтический препарат на основе интерферона (варианты)

Country Status (24)

Country Link
US (1) US5830455A (enExample)
EP (1) EP0675730B1 (enExample)
JP (2) JP2849214B2 (enExample)
KR (1) KR100309059B1 (enExample)
CN (1) CN1094642A (enExample)
AT (1) ATE199643T1 (enExample)
AU (1) AU680858B2 (enExample)
CA (1) CA2152389A1 (enExample)
DE (1) DE69330032T2 (enExample)
ES (1) ES2156150T3 (enExample)
FR (1) FR2699407A1 (enExample)
GB (1) GB9226729D0 (enExample)
HR (1) HRP931510A2 (enExample)
HU (1) HUT72965A (enExample)
IL (1) IL108114A (enExample)
IT (1) IT1261949B (enExample)
MY (1) MY141415A (enExample)
NO (1) NO952469D0 (enExample)
PL (1) PL309398A1 (enExample)
RU (1) RU2145235C1 (enExample)
TW (1) TW286283B (enExample)
WO (1) WO1994014473A1 (enExample)
YU (1) YU79393A (enExample)
ZA (1) ZA939583B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242243C2 (ru) * 2001-09-27 2004-12-20 Вертелецкий Павел Васильевич Композиции и способы потенцирования терапевтических эффектов интерферонов

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
DE4325547C2 (de) * 1993-07-29 1997-11-27 Max Planck Gesellschaft Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
US6020205A (en) * 1998-04-10 2000-02-01 Immunosciences Lab, Inc. Determination of intracellular antioxidant levels
RU2156134C2 (ru) * 1998-05-12 2000-09-20 ООО "Формавит" Биофармацевтический препарат на основе живой культуры bacillus и способ лечения заболевания инфекционной природы
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) * 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
US6759061B2 (en) * 2001-08-31 2004-07-06 Renew Life, Inc. Liver function improvement formulation
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US20030158213A1 (en) * 2001-11-16 2003-08-21 Freeman Bruce A. Xanthine oxidase inhibition as a strategy to alleviate oxidative impairment of vascular function
CA2489552A1 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
CA2509955A1 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
EP1626692A4 (en) * 2003-03-28 2008-12-10 Pharmasset Inc COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP1655292B1 (en) * 2003-07-22 2015-04-29 Kyowa Hakko Bio Co., Ltd Preventive or therapeutic composition for viral infectious disease
PL1658302T3 (pl) 2003-07-25 2011-03-31 Idenix Pharmaceuticals Inc Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
JP2005104852A (ja) * 2003-09-29 2005-04-21 Kyowa Hakko Kogyo Co Ltd モービリウィルス感染症の予防または治療用組成物
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
CA2580457C (en) 2004-09-14 2014-11-04 Pharmasset, Inc. Preparation of 2'­fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
ES2422290T3 (es) 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
US10838095B2 (en) 2010-08-05 2020-11-17 Pgs Geophysical As Wavefield deghosting of seismic data recorded using multiple seismic sources at different water depths
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636383A (en) * 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526205A (en) * 1974-11-07 1978-09-27 Searle & Co Treatment of interferon-like material
US4100150A (en) * 1975-11-04 1978-07-11 G. D. Searle & Co. Stabilization of interferon against mechanical stress using thioctic acid
US4762705A (en) * 1981-11-10 1988-08-09 Adolf W. Schwimmer Cancer therapy with interferon
US4927762A (en) * 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
CH666814A5 (it) * 1986-07-24 1988-08-31 Inpharzam Int Sa Composizione farmaceutica idrosolubile contenente n-acetil-cisteina.
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
CA1321349C (en) * 1986-11-21 1993-08-17 Robert Zimmerman Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein
IT1231012B (it) * 1989-07-27 1991-11-08 Zambon Spa Composizione farmaceutica per uso orale contenente nac.
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
EP0486912B1 (de) * 1990-11-19 1996-02-07 Manz Galvano-Technik GmbH. Sperr- und Dränagevorrichtung für Tauchtrommeln bei der galvanischen und/oder chemischen Oberflächenbehandlung von Massenteilen
JP2597953B2 (ja) 1991-12-10 1997-04-09 大塚製薬株式会社 制癌剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636383A (en) * 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fujita J.et al. "Tnduction of endogenous IFN-α..." Nature. V.337, 270-272, 1989. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242243C2 (ru) * 2001-09-27 2004-12-20 Вертелецкий Павел Васильевич Композиции и способы потенцирования терапевтических эффектов интерферонов

Also Published As

Publication number Publication date
NO952469L (no) 1995-06-20
IL108114A (en) 1999-12-31
EP0675730A1 (en) 1995-10-11
MY141415A (en) 2010-04-30
ITRM930840A0 (it) 1993-12-21
JP2849214B2 (ja) 1999-01-20
US5830455A (en) 1998-11-03
GB9226729D0 (en) 1993-02-17
AU5707694A (en) 1994-07-19
HUT72965A (en) 1996-06-28
HRP931510A2 (en) 1995-12-31
DE69330032D1 (de) 2001-04-19
EP0675730B1 (en) 2001-03-14
FR2699407A1 (fr) 1994-06-24
KR100309059B1 (ko) 2002-06-20
CA2152389A1 (en) 1994-07-07
JPH08504799A (ja) 1996-05-21
ITRM930840A1 (it) 1995-06-21
WO1994014473A1 (en) 1994-07-07
TW286283B (enExample) 1996-09-21
IT1261949B (it) 1996-06-04
ES2156150T3 (es) 2001-06-16
JPH06234657A (ja) 1994-08-23
CN1094642A (zh) 1994-11-09
ATE199643T1 (de) 2001-03-15
ZA939583B (en) 1995-05-22
YU79393A (sh) 1996-10-09
NO952469D0 (no) 1995-06-20
HU9501841D0 (en) 1995-08-28
IL108114A0 (en) 1994-04-12
PL309398A1 (en) 1995-10-02
DE69330032T2 (de) 2001-09-06
AU680858B2 (en) 1997-08-14

Similar Documents

Publication Publication Date Title
RU2145235C1 (ru) Терапевтическая комбинация, содержащая человеческий интерферон, фармацевтический препарат на основе интерферона (варианты)
Beloqui et al. N-acetyl cysteine enhances the response to interferon-α in chronic hepatitis C: a pilot study
Bonkovsky Therapy of hepatitis C: other options
KR19990082084A (ko) 인터페론으로 선행치료한 hcv 환자를 재치료하기 위한 제약학적 조성물
Manns et al. Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1
KR20140035305A (ko) C형 간염 바이러스 감염의 새로운 치료법
KR100394382B1 (ko) 천연사람α-인터페론으로구성된약학조성물
JPH06279309A (ja) インターフェロン処置非応答者に対するｃ型肝炎の処置剤
AU746648B2 (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
SI9300671A (sl) Terapevtska kombinacija, ki vsebuje humani interferon, uporabna za zdravljenje virusnih in nevirusnih infekcij
US20060067913A1 (en) HCV therapy
JP2014509628A (ja) Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル
Sarin What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C?
EFFECTIVENESS et al. ETR SR
MXPA00002570A (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
MXPA06007734A (es) Agente preventivo para carcinogenesis de cancer de higado que contiene un compuesto basado en quinona como ingrediente activo.
JPH07258109A (ja) Ｃ型肝炎の処置法および処置用組成物